Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 61 articles: HTML format

Single Articles

March 2020
1. NEHRING P, Przybylkowski A
   Think twice before operating on a pancreatic mass: could it be IgG4-related disease?
   Lancet. 2020;395:816.
   PubMed    
   
   
   February 2020
2. SEN A, Jette N, Husain M, Sander JW, et al
   Epilepsy in older people.
   Lancet. 2020;395:735-748.
   PubMed     Abstract available
   
   
   January 2020
3. GARRETT C, Ismail K
   Forgotten: mental health interventions in type 1 diabetes.
   Lancet. 2020;395:115.
   PubMed    
   
   
   November 2019
4. TEKTONIDOU MG
   JAK inhibitors: promising for a wider spectrum of autoimmune diseases?
   Lancet. 2019 Nov 11. pii: S0140-6736(19)32681.
   PubMed    
   
   
   October 2019
5. BRUINSTROOP E, Cairo I, Drillenburg P, van Dam PS, et al
   Hypothyroidism to Graves' disease and late appearance of pretibial myxoedema.
   Lancet. 2019;394:1364.
   PubMed    
   
   
   
6. SILBERMANN E, Bourdette D
   A new era for neuromyelitis optica spectrum disorder.
   Lancet. 2019;394:1304-1305.
   PubMed    
   
   
   
7. CREE BAC, Bennett JL, Kim HJ, Weinshenker BG, et al
   Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
   Lancet. 2019;394:1352-1363.
   PubMed     Abstract available
   
   
   September 2019
8. BECK RW, Bergenstal RM, Laffel LM, Pickup JC, et al
   Advances in technology for management of type 1 diabetes.
   Lancet. 2019 Sep 13. pii: S0140-6736(19)31142.
   PubMed     Abstract available
   
   
   
9. DAYAN CM, Korah M, Tatovic D, Bundy BN, et al
   Changing the landscape for type 1 diabetes: the first step to prevention.
   Lancet. 2019 Sep 13. pii: S0140-6736(19)32127.
   PubMed     Abstract available
   
   
   
10. VANTYGHEM MC, de Koning EJP, Pattou F, Rickels MR, et al
    Advances in beta-cell replacement therapy for the treatment of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31334.
    PubMed     Abstract available
    
    
    
11. SCHMIDT E, Kasperkiewicz M, Joly P
    Pemphigus.
    Lancet. 2019;394:882-894.
    PubMed     Abstract available
    
    
    June 2019
12. DORNER T, Furie R
    Novel paradigms in systemic lupus erythematosus.
    Lancet. 2019;393:2344-2358.
    PubMed     Abstract available
    
    
    
13. DURCAN L, O'Dwyer T, Petri M
    Management strategies and future directions for systemic lupus erythematosus in adults.
    Lancet. 2019;393:2332-2343.
    PubMed     Abstract available
    
    
    May 2019
14. LUO J, Gonsalves G, Greene J
    Insulin for all: treatment activism and the global diabetes crisis.
    Lancet. 2019;393:2116-2117.
    PubMed    
    
    
    April 2019
15. ELAGHA A, Mohsen A
    Cardiac MRI clinches diagnosis of Libman-Sacks endocarditis.
    Lancet. 2019;393:e39.
    PubMed    
    
    
    
16. MCCALL B
    Alemtuzumab to be restricted pending review, says EMA.
    Lancet. 2019;393:1683.
    PubMed    
    
    
    March 2019
17. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed    
    
    
    
18. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed    
    
    
    
19. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed    
    
    
    February 2019
20. YUAN K, Huang G, Sang X, Xu A, et al
    Baricitinib for systemic lupus erythematosus.
    Lancet. 2019;393:402.
    PubMed    
    
    
    
21. WALLACE DJ, Furie RA, Tanaka Y, de Bono S, et al
    Baricitinib for systemic lupus erythematosus - Authors' reply.
    Lancet. 2019;393:402-403.
    PubMed    
    
    
    January 2019
22. POWER SP, O'Mahony D
    Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
    Lancet. 2019;393:349.
    PubMed    
    
    
    December 2018
23. THE LANCET
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.
    PubMed    
    
    
    October 2018
24. COSTEDOAT-CHALUMEAU N, Houssiau FA
    Ustekinumab: a promising new drug for SLE?
    Lancet. 2018;392:1284-1286.
    PubMed    
    
    
    
25. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
    PubMed    
    
    
    
26. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Abstract available
    
    
    September 2018
27. VAN VOLLENHOVEN RF, Hahn BH, Tsokos GC, Wagner CL, et al
    Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    Lancet. 2018 Sep 21. pii: S0140-6736(18)32167.
    PubMed     Abstract available
    
    
    
28. LEBWOHL B, Sanders DS, Green PH
    Coeliac disease and dermatitis herpetiformis - Authors' reply.
    Lancet. 2018;392:917.
    PubMed    
    
    
    
29. RODRIGUES F, Bachmeyer C
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916.
    PubMed    
    
    
    
30. CAIO G, De Giorgio R, Volta U
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916-917.
    PubMed    
    
    
    
31. FLUME PA, Chalmers JD, Olivier KN
    Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.
    Lancet. 2018;392:880-890.
    PubMed     Abstract available
    
    
    
32. PERL A, Lai ZW, Kelly R, Faraone SV, et al
    Sirolimus for systemic lupus erythematosus - Authors' reply.
    Lancet. 2018;392:734.
    PubMed    
    
    
    
33. HU HQ, Lee FJ, Garsia R
    Sirolimus for systemic lupus erythematosus.
    Lancet. 2018;392:733-734.
    PubMed    
    
    
    August 2018
34. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    PubMed    
    
    
    
35. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Abstract available
    
    
    July 2018
36. WALLACE DJ, Furie RA, Tanaka Y, Kalunian KC, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:222-231.
    PubMed     Abstract available
    
    
    
37. MUCKE J, Schneider M
    Baricitinib for systemic lupus erythematosus.
    Lancet. 2018;392:190-192.
    PubMed    
    
    
    June 2018
38. XIAO F, Tian X, Wang XF
    Antiphospholipid syndrome causing reversible internal carotid artery thrombosis.
    Lancet. 2018;391:2641.
    PubMed    
    
    
    
39. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Abstract available
    
    
    March 2018
40. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    PubMed    
    
    
    
41. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    PubMed    
    
    
    
42. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    PubMed    
    
    
    
43. METZ LM, Liu WQ
    Effective treatment of progressive MS remains elusive.
    Lancet. 2018;391:1239-1240.
    PubMed    
    
    
    
44. KAPPOS L, Bar-Or A, Cree BAC, Fox RJ, et al
    Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30475.
    PubMed     Abstract available
    
    
    
45. THOMPSON AJ, Baranzini SE, Geurts J, Hemmer B, et al
    Multiple sclerosis.
    Lancet. 2018 Mar 22. pii: S0140-6736(18)30481.
    PubMed     Abstract available
    
    
    
46. THE LANCET
    End of the road for daclizumab in multiple sclerosis.
    Lancet. 2018;391:1000.
    PubMed    
    
    
    
47. LAI ZW, Kelly R, Winans T, Marchena I, et al
    Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30485.
    PubMed     Abstract available
    
    
    
48. FERNANDEZ DR, Crow MK
    CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematous.
    Lancet. 2018 Mar 15. pii: S0140-6736(18)30544.
    PubMed    
    
    
    February 2018
49. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    PubMed    
    
    
    
50. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Abstract available
    
    
    January 2018
51. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    PubMed    
    
    
    December 2017
52. TSUDA K, Tanimoto T, Mori J, Kosugi K, et al
    Targeted-release budesonide therapy for IgA nephropathy.
    Lancet. 2017;390:2625.
    PubMed    
    
    
    
53. FELLSTROM B, Barratt J, Floge J, Jardine A, et al
    Targeted-release budesonide therapy for IgA nephropathy - Authors' reply.
    Lancet. 2017;390:2625-2626.
    PubMed    
    
    
    October 2017
54. GREEN AJ, Gelfand JM, Cree BA, Bevan C, et al
    Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
    Lancet. 2017 Oct 10. pii: S0140-6736(17)32346.
    PubMed     Abstract available
    
    
    
55. RUBIN R
    Mary Crow: leader in research on systemic lupus erythematosus.
    Lancet. 2017;390:1636.
    PubMed    
    
    
    September 2017
56. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    PubMed    
    
    
    
57. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Abstract available
    
    
    March 2017
58. WYATT RJ
    Are we ready for targeted therapy for IgA nephropathy?
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30820.
    PubMed    
    
    
    
59. FELLSTROM BC, Barratt J, Cook H, Coppo R, et al
    Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30550.
    PubMed     Abstract available
    
    
    December 2016
60. EL-KHATIB FH, Balliro C, Hillard MA, Magyar KL, et al
    Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    Lancet. 2016 Dec 20. pii: S0140-6736(16)32567.
    PubMed     Abstract available
    
    
    September 2016
61. BOLINDER J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, et al
    Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
    Lancet. 2016 Sep 9. pii: S0140-6736(16)31535.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: